LUPIN LIMITED : RECEIVES TENTATIVE APPROVAL FROM U.S. FDA

• Lupin received tentative approval from the U.S. FDA for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL. • The product is an oral liquid formulation of apixaban, an alternative for adult patients requiring anticoagulation therapy who may have difficulty swallowing tablets. • Upon final approval, the product will be manufactured at Lupin's Somerset, New Jersey facility.

Lupin Ltd

Open attachment

← Back to feed